Key Highlights
- Aleniglipron, Structure Therapeutics’ oral GLP-1 medication, achieved 16.3% placebo-adjusted weight reduction at 44 weeks during the ACCESS II Phase 2 trial
- Performance exceeded oral GLP-1 candidates from Novo Nordisk (13.6%) and Eli Lilly (12.4%) based on Phase 2 findings
- Data demonstrated continued weight reduction without reaching a plateau, distinguishing it from competitor drugs
- Shares of GPCR climbed approximately 10% on Monday, reaching roughly $59.80 following the announcement
- Company plans end-of-Phase 2 FDA consultation during Q2 2026, targeting Phase 3 initiation in H2 2026
Structure Therapeutics delivered compelling Phase 2 trial results for aleniglipron, its oral GLP-1 candidate, on Monday morning, propelling GPCR shares upward by approximately 10% during early market hours.
Structure Therapeutics Inc., GPCR
The ACCESS II clinical trial demonstrated 16.3% placebo-adjusted weight reduction with the 180 mg dosage and 16.0% with the 240 mg dosage following 44 weeks of treatment. Both dosing levels continued to show weight loss progression without plateauing.
These figures stand favorably against competing therapies. Novo Nordisk’s oral Wegovy formulation achieved 13.6% weight loss during Phase 3 trials. Eli Lilly’s orforglipron produced approximately 12.4% weight reduction in Phase 2 testing, later showing 11.2% in Phase 3 evaluation.
Previously released December data had demonstrated 14.2% weight loss at a reduced dose level. Participants maintaining that lower dosage throughout a 53-week period ultimately achieved 16% weight reduction, indicating sustained therapeutic benefits over extended treatment durations.
Safety and tolerability metrics remained favorable. The ACCESS Open Label Extension study recorded merely 2% discontinuation rates related to adverse events. Body composition analysis showed a 3.4% discontinuation rate. The company employs a conservative 2.5 mg initial dose, which appears to support patient adherence and treatment continuation.
The positive outcomes have sparked acquisition speculation. H.C. Wainwright analyst Ananda Ghosh had previously identified aleniglipron earlier this month as “the most acquirable asset in obesity.” The firm elevated its price target to $114. Citizens maintained a Market Outperform rating while adjusting its target downward to $113.
Analyst Reactions
Leerink Partners confirmed its Outperform rating and $90 price target following the data release. The firm emphasized the favorable tolerability profile and clear dose-response relationship as significant strengths.
RBC Capital Markets adopted a more cautious stance. Analyst Trung Huynh observed that orforglipron demonstrated comparable Phase 2 performance before delivering more modest Phase 3 results. He identified an atypically low weight gain rate within the placebo cohort as a statistical anomaly requiring further scrutiny. RBC maintained its Outperform rating on Lilly with a $1,250 price target.
“These results require a more comprehensive data set before we can determine whether they represent meaningful differentiation from Orfo or oral Wegovy,” Huynh stated.
What Comes Next
Structure Therapeutics has scheduled an end-of-Phase 2 consultation with the FDA during Q2 2026. Phase 3 trials are projected to commence in the second half of 2026. The company will use Phase 2 data from both elevated dosing levels to determine which concentration advances to late-stage development.
Heading into Monday’s trading session, the stock remained down 23% year-to-date, though it has delivered 155% gains over the trailing 12 months. At $59.80, shares trade substantially below analyst consensus projections, which span from $90 to $140.
Cantor Fitzgerald had earlier identified this 44-week data release as a probable catalyst for stock movement. That projection materialized accurately.
Monday’s price appreciation elevated GPCR’s market capitalization to roughly $3.81 billion.
